Other hereditary or degenerative neurological disorders

This collection of diseases encompasses a wide range of conditions, categorised by their symptomatic impact upon the neurological system. Pathogenesis and epidemiology are

...


Read more on Other hereditary or degenerative neurological disorders

 

 

Latest news articles

Added 24 days ago Drug news

FDA approves Zolgensma to treat spinal muscular atrophy.

AveXis, a Novartis company, announced that the FDA has approved Zolgensma (onasemnogene abeparvovac-xioi), one-time dose of gene therapy, for...

Added 1 month ago Drug news

NICE recommends Spinraza for the treatment of spinal muscular atrophy

Biogen Inc.has announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding...

Added 1 month ago Drug news

Genentech presents pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy

Genentech, a member of the Roche Group announced new data from the dose-finding Part 1 of the pivotal FIREFISH trial...

Search all news articles for Other hereditary or degenerative neurological disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Guidelines

Spasticity in under 19s: management

This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders.

Added 6 years ago

EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force

Objectives: To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an expert panel.

Added 7 years ago

Use of antibody testing in nervous system disorders

To evaluate service provision and quality assurance schemes for clinically useful autoantibody tests in neurology.

Added 7 years ago

Search all guidelines for Other hereditary or degenerative neurological disorders
 

Journal articles

The diagnosis of progressive supranuclear palsy: current opinions and challenges.

Introduction: Progressive supranuclear palsy (PSP) is associated with microtubule-associated protein tau dysfunction. Originally thought to result in a syndrome of atypical Parkinsonism, vertical supranuclear gaze palsy...

Added 6 days ago

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology.

Added 6 days ago

Anti-inflammatory drug use and progressive supranuclear palsy.

Background: Anti-inflammatory drug use, particularly ibuprofen, has been associated with a lower risk of Parkinson's disease. Microglial activation and inflammatory cytokine expression have been shown to be pathological...

Added 6 days ago

Search all journal articles for Other hereditary or degenerative neurological disorders
 

Clinical trials

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092...

Added 7 days ago

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP). The study will also assess the pharmacodynamic...

Added 7 days ago

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 96 weeks, in patients with CLN2.

Added 1 year ago

Search all clinical trials for Other hereditary or degenerative neurological disorders
 

CME

Huntington's disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
1
Subscription fee
0

Cerebral palsy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Motor neurone disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Other hereditary or degenerative neurological disorders